Dolors Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dolors Costa has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- María Rozman
Hematopathology Section, Pathology Department CDB, Hospital Clínic Barcelona Barcelona Spain
8 shared publications - Ana Carrió
Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona
7 shared publications - Elias Campo
Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
7 shared publications - Dolors Colomer
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
6 shared publications Jordi Esteve
5 shared publicationsAmparo Arias
4 shared publications
Latest Publications
- Open Access
- 21 December 2015
- Published by Springer Nature in Cancer Cell International
- Vol. 15 (1) , 1-7
Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma
The resulting clinical impact of the combined use of G-CSF with chemotherapy as a chemosensitizing strategy for treatment of acute myeloid leukemia (AML) patients is still controversial. In this study, the effect of ex vivo treatment with G-CSF on AML primary blasts was studied. Peripheral blood mononuclear cells from AML patients were treated with G-CSF at increasing doses, alone or in co-culture with HS-5 stromal cells. Cell viability and surface phenotype was determined by flow cytometry 72 h after treatment. For clonogenicity assays, AML primary samples were treated for 18 h with G-CSF at increasing concentrations and cultured in methyl-cellulose for 14 days. Colonies were counted based on cellularity and morphology criteria. The presence of G-CSF reduced the overall viability of AML cells co-cultured with bone marrow stroma; whereas, in absence of stroma, a negligible effect was observed. Moreover, clonogenic capacity of AML cells was significantly reduced upon treatment with G-CSF. Interestingly, reduction in the AML clonogenic capacity correlated with the sensitivity to chemotherapy observed in vivo. These ex vivo results would provide a biological basis to data available from studies showing a clinical benefit with the use of G-CSF as a priming agent in patients with a chemosensitive AML and would support implementation of further studies exploring new strategies of chemotherapy priming in AML.
- 21 December 2015
- Published by Springer Nature in Cancer Cell International
- Vol. 15 (1) , 1-7
Open AccessTreatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma
The resulting clinical impact of the combined use of G-CSF with chemotherapy as a chemosensitizing strategy for treatment of acute myeloid leukemia (AML) patients is still controversial. In this study, the effect of ex vivo treatment with G-CSF on AML primary blasts was studied. Peripheral blood mononuclear cells from AML patients were treated with G-CSF at increasing doses, alone or in co-culture with HS-5 stromal cells. Cell viability and surface phenotype was determined by flow cytometry 72 h after treatment. For clonogenicity assays, AML primary samples were treated for 18 h with G-CSF at increasing concentrations and cultured in methyl-cellulose for 14 days. Colonies were counted based on cellularity and morphology criteria. The presence of G-CSF reduced the overall viability of AML cells co-cultured with bone marrow stroma; whereas, in absence of stroma, a negligible effect was observed. Moreover, clonogenic capacity of AML cells was significantly reduced upon treatment with G-CSF. Interestingly, reduction in the AML clonogenic capacity correlated with the sensitivity to chemotherapy observed in vivo. These ex vivo results would provide a biological basis to data available from studies showing a clinical benefit with the use of G-CSF as a priming agent in patients with a chemosensitive AML and would support implementation of further studies exploring new strategies of chemotherapy priming in AML.
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S189-S190
G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S189-S190
G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells
- 15 November 2012
- Published by S. Karger AG in Acta Haematologica
- Vol. 129 (2) , 65-71
Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies
Significant progress in the understanding of the genetic basis of acute myeloid leukemia (AML) has been made during the last 30 years. The aim of the present study was to assess whether the detection of recurrent gene rearrangements by fluorescent in situ hybridization (FISH) studies and NPM1 and FLT3 gene mutations by molecular studies added clinically relevant information to the karyotype in 113 AML patients. Thus, FISH and molecular studies were found to add new information in 22 and 55% of the patients, respectively, particularly in cases with normal karyotype (NK) or when a cytogenetic analysis failed. Patients with NK changed their genetic risk group to favorable in 27 and 29% of cases using FISH and molecular biology studies, respectively. Our results demonstrate that molecular biology and FISH studies provide relevant information in AML and should be routinely performed.
- 15 November 2012
- Published by S. Karger AG in Acta Haematologica
- Vol. 129 (2) , 65-71
Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies
Significant progress in the understanding of the genetic basis of acute myeloid leukemia (AML) has been made during the last 30 years. The aim of the present study was to assess whether the detection of recurrent gene rearrangements by fluorescent in situ hybridization (FISH) studies and NPM1 and FLT3 gene mutations by molecular studies added clinically relevant information to the karyotype in 113 AML patients. Thus, FISH and molecular studies were found to add new information in 22 and 55% of the patients, respectively, particularly in cases with normal karyotype (NK) or when a cytogenetic analysis failed. Patients with NK changed their genetic risk group to favorable in 27 and 29% of cases using FISH and molecular biology studies, respectively. Our results demonstrate that molecular biology and FISH studies provide relevant information in AML and should be routinely performed.
- 25 July 2012
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (11) , 1064-1065
NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12
- 25 July 2012
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (11) , 1064-1065
NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12
- 30 September 2011
- Published by Elsevier in Leukemia Research
- Vol. 35 (9) , 1276-1278
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation
- 30 September 2011
- Published by Elsevier in Leukemia Research
- Vol. 35 (9) , 1276-1278
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation
- Open Access
- 14 December 2010
- Published by Wiley in American Journal of Hematology
- Vol. 86 (3) , 245-250
Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support
- 14 December 2010
- Published by Wiley in American Journal of Hematology
- Vol. 86 (3) , 245-250
Open AccessTransfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support
- 30 November 2010
- Published by Elsevier in Leukemia Research
- Vol. 34 (11) , 1437-1441
Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?
- 30 November 2010
- Published by Elsevier in Leukemia Research
- Vol. 34 (11) , 1437-1441
Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?
- 15 October 2006
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 170 (2) , 115-120
Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements
- 15 October 2006
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 170 (2) , 115-120
Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements
- 1 April 2006
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 166 (1) , 89-93
Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia
- 1 April 2006
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 166 (1) , 89-93
Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia
- 1 November 2003
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 147 (1) , 36-43
High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia
- 1 November 2003
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 147 (1) , 36-43
High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia